ClinicalTrials.gg
WithdrawnNCT01593072Updated Jan 24, 2013

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

A Phase 1 interventional study of AVI-7537 and Normal Saline Solution (NSS) in Ebola Hemorrhagic Fever, sponsored by Sarepta Therapeutics, Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-24.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Terminated for convenience of the Government due to funding constraits

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Hemorrhagic Fever, Ebola with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Hemorrhagic Fever, Ebola · United States.

Enrollment
27th of 27
0 · median 48
Started
2012
with 1 other
Phase 1
20 of 28
1 open now
Registered
7th of 28
by date
Lead sponsor
2 of 28
Sarepta Therapeutics, Inc.

Among the 28 studies in Hemorrhagic Fever, Ebola with a site in United States, this one is the 27th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2012, is one of 20 in phase 1, and was the 7th registered.

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

Browse Hemorrhagic Fever, Ebola studies →

Open to participants now

1 of the 28 studies in Hemorrhagic Fever, Ebola with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Hemorrhagic Fever, Ebola studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hemorrhagic Fever, Ebola with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).

Read the detailed description

The purpose of this study is to evaluate the safety and tolerability of 14 once daily intravenous (IV) infusions of ascending doses of AVI 7537 compared to matched placebo in healthy male and female subjects.

To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects

03

Conditions studied

  • Ebola Hemorrhagic Fever

Keywords

  • Multiple Ascending Dose (MAD)
  • Ebola Virus
  • Post Exposure Prophylaxis
  • EHF
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject must meet all of the following criteria to be eligible for this study.

  1. Man or woman 18 to 50 years of age, inclusive, at the time of screening.
  2. 18 kg/m2 to 35 kg/m2, inclusive, at the time of screening and Check-in (Day -1).
  3. Good general health (no chronic health conditions) as determined by the Investigator.
  4. Female subjects must be of non- (e.g., be confirmed or have undergone surgical sterilization) or must, in conjunction with their sexual partner(s), use 2 forms of medically acceptable (e.g., oral contraception in conjunction with a male condom) during the screening period and for the entire duration of the study including the 28-day post last dose follow-up.
  5. Male subjects must either be sterile or agree to use, for the entire duration of the study including the 28 day post last dose follow-up, a male condom and the female sexual partner must also use a medically acceptable form of birth control (e.g. oral contraceptives).
  6. Male subjects must agree to not donate sperm for at least 30 days after the last infusion of study medication.
  7. Able to understand the requirements of the study, to provide written (as evidenced by signature on an informed consent document that is approved by an Institutional Review Board [IRB]), and agreeable to abiding by the study restrictions.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from this study.

  1. Pregnancy or breastfeeding.
  2. A positive urine or blood screen for drugs of abuse, including alcohol.
  3. Use of any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to Check-in (Day -1).
  4. A positive cotinine test indicating recent nicotine use.
  5. Donated blood within 90 days or plasma within 30 days of first dose on Day 1.
  6. Active substance abuse or any medical or psychiatric condition that could jeopardize the subject's safety or the subject's ability to comply with the protocol.
  7. Use of any medications apart from vitamins, acetaminophen, or hormonal within 14 days of first dose on Day 1. Subjects with mild seasonal allergies may use antihistamines at the discretion of the Investigator after approval by the Sponsor Medical Monitor.
  8. Participation in any interventional clinical trial within 45 days of first dose on Day 1 (i.e., received any other drug).
  9. Recipient of an organ transplant (solid or hematopoietic).
  10. Prolonged interval > 440 ms for males or > 460 ms for females using the average of the triplicate (ECGs) collected during screening, on Day -1, or just prior to dosing on Day 1.
  11. Other ECG abnormality, as determined by the Investigator.
  12. Any clinically significant abnormal hematology, chemistry, coagulation, or urinalysis value, as determined by the Investigator.
  13. (GFR) of \< 80 mL/min, based on the Modification of Diet in Renal Disease equation.
  14. Urine-albumin-to-creatinine ratio (UACR) > 30 mg/g.
  15. Positive test for (HIV-1 serology) or known HIV infection.
  16. Positive result for surface antigen (HBsAg) or for virus (HCV) antibody.
  17. Use of alcohol-containing foods or beverages within 72 hours prior to Check-in on Day -1.
  18. Use of caffeine-containing foods or beverages within 24 hours prior to Check-in on Day -1.
  19. Febrile illness or significant infection within 48 hours before administration of the first dose of study drug on Day 1.

Note: Inclusion of each subject will be reviewed with a member of AVI BioPharma Clinical Personnel prior to enrollment in the trial. Written approval from a member of AVI BioPharma Clinical Personnel is required prior to randomization.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    AVI-7537

    AVI-7537

    Drug: AVI-7537

  • Other
    Placebo

    Normal Saline Solution (NSS)

    Other: Normal Saline Solution (NSS)

Interventions

  • DrugAVI-7537

    Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.

  • OtherNormal Saline Solution (NSS)

    Normal Saline Solution (NSS)

06

What researchers measure

Primary outcomes

  1. The outcome measures are Serial PK Day 1 over 24 hrs(pre-dose,10 min post,30 min post, 1hr 1.5,2,4,6, 8, 12,16,24,28,32,36, and 48 hrs post-dose), daily through level and on Day 14 (last day of dosing) serial PK until 48 hrs post last dose.

    The outcome measures are Serial PK Day 1 over 24 hours (pre-dose, 10 minutes post-dose , 30 minutes, 1 hour, 1.5, 2, 4, 6,. 8, 12,16,24 hours post-dose), daily trough level and on Day 14 (last day of dosing). PK Day 14 over 48 hours (post-dose, 10 minutes, 1.5, 2, 4, 6, 8, 12, 16, 24, 28, 32, 36, and 48 hours post-dose (collection of plasma pre-dose on Day 14 will also serve as the trough sample for that day).

    Time frame: 2 weeks

Secondary outcomes

  1. To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects,

    Efficacy will not be assessed in a Phase I study.

    Time frame: 2 weeks

07

Study locations

1 site
  • Quintiles Phase I Services
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 7, 2012
Start
Aug 2012
Primary completionEst.
Jan 2013
CompletionEst.
Jan 2013
Last update
Jan 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01593072
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
May 7, 2012
Start date
Aug 2012
Primary completion
Jan 2013 (estimated)
Completion
Jan 2013 (estimated)
Last update
Jan 24, 2013

Study contacts

Alison Heald, MD
principal investigator · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion